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Summary 
Characterisation of receptors can involve either assessment of their ability to bind ligands or 
measure receptor activation as a result of agonist or inverse agonist interactions. This 
review focuses on G protein-coupled receptors (GPCRs), examining techniques that can be 
applied to both receptors in membranes and after solubilisation. Radioligand binding 
remains a widely used technique, although there is increasing use of fluorescent ligands. 
These can be used in a variety of experimental designs, either directly monitoring ligand 
itself with techniques such as fluorescence polarisation or indirectly via resonance energy 
transfer (fluorescence/Forster resonance energy transfer, FRET and bioluminescence 
resonance energy transfer, BRET). Label free techniques such as isothermal titration 
calorimetry (ITC) and surface plasmon resonance (SPR) are also increasingly being used. For 
GPCRs, the main measure of receptor activation is to investigate the association of the G 
protein with the receptor. The chief assay measures the receptor-stimulated binding of GTP 
or a suitable analogue to the receptor. The direct association of the G protein with the 
receptor has been investigated via resonance energy techniques. These have also been used 
to measure ligand-induced conformational changes within the receptor; a variety of 
experimental techniques are available to incorporate suitable donors and acceptors within 
the receptor.  
 
1. Introduction 
The drive for improved methods of membrane protein isolation comes from the desire to preserve 
as much of their functionality as possible. This has led to the introduction of new detergents, 
methods that remove detergent immediately after solubilisation and completely detergent-free 
protocols [1]. An obvious corollary of these developments is that there are robust methods for 
measuring receptor function before and after isolation. Of perhaps even greater importance is the 
need to ensure that a genetically modified receptor retains appropriate properties; the introduction 
of a point mutation or an epitope tag can seriously impair its function. The techniques can be divided 
into two broad approaches. One is to examine ligand binding, the other is to measure the ability of 
the receptor to signal. The latter is generally a more complete measure of functionality, but 
becomes more demanding when the receptor is removed from the cell.  
There are a multitude of techniques available for measuring receptor activity in cells and 
membranes, prior to solubilisation. A full review of these is beyond the scope of the current article; 
they are dealt with by others [2-4]. This article will focus on techniques that can be used to measure 
function in receptors both in membranes and after solubilisation. The latter is much more 
demanding than the former. For some receptors such as ligand-gated ion channels, any assay of 
function almost inevitably requires the receptor to be in a lipid bilayer and thus requires 
reconstitution. However, for other receptors, it is possible to carry out assays when they are still in 
solution. In this review, we will concentrate on techniques that have been developed for G protein-
coupled receptors (GPCRs1); variants of many of these can be applied to other receptors with 
enzymic activity such as tyrosine kinase receptors.  
2. Binding assays 
                                                        
1
 Abbreviations: bioluminescence resonance energy transfer, BRET; fluorescence/Forster resonance energy 
transfer, FRET; G protein-coupled receptors, GPCRs; isothermal titration calorimetry, ITC; surface plasmon 
resonance, SPR. 
  
2.1. Theoretical perspectives  
The binding of a ligand to receptor is usually described by the law of mass action [5]. At equilibrium, 
the rate at which the ligand, L, binds to the receptor, R, governed by the association rate constant, 
kon, is equal to the rate at which the ligand-receptor complex, LR, dissociates back to L and R, 
governed by the dissociation rate constant, koff. Thus: 
 [L][R]kon = [LR]koff (1), 
so [L][R]/[LR] = koff/kon =Kd, the dissociation constant for the ligand at the receptor (2). 
If the total number of receptors for L is Bmax and b is the number occupied when it is present at 
concentration [L], then  
b = Bmax[L]
n
/([L]
n
 + Kd) (3), where n is the Hill coefficient; this is a form of the Hill equation. 
When n=1, this is consistent with a 1:1 interaction between ligand and receptor. When n>1, the 
results are conventionally interpreted in terms of positive co-operativity, implying the receptor has 
multiple binding sites for the ligand and the binding of the first ligand molecule makes it easier for 
the second to bind. When n<1, there may be negative co-operativity or the the ligand may be 
binding to more than one type of receptor or binding site.   
Equation 3 can be usefully simplified to give the fractional occupancy of the receptor, b/Bmax, 
simply by dividing both sides by Bmax [6]. It is also usually reformulated for Log[L] rather than [L]. 
This, the “logistic Hill” equation, gives a sigmoidal curve where n describes the slope of the linear 
part of the line. The upper asymptote is equal to the Bmax and the Kd is the concentration of ligand 
needed to occupy half the receptors. However, there will almost certainly be some non-specific 
binding associated with the ligand. Non-specific binding can be to other receptors in the 
preparation, reflecting poor selectivity of the ligand but it can also arise from low affinity 
interactions with the membranes (or detergent micelles) or filters and microfuge tubes that are 
integral to the assay. It increases linearly with the concentration of ligand and this needs to 
considered when the total binding of the receptor is measured. Non-specific binding is assessed by 
conducting parallel assays. In one set, the total binding of the ligand is measured. In the other set, 
the specific binding of the ligand to the receptor is blocked by inclusion of another agent that 
saturates all the receptors, leaving only the non-specific binding. Ideally this agent should be 
structurally dissimilar to the labelled ligand, although that is not always possible [6, 7]. 
The most straightforward experimental design is saturation binding, where the receptor is incubated 
with increasing amounts of labelled ligand. This gives a binding curve that should saturate as the 
Bmax is approached. Importantly, any assay based on this design will give information on the 
number of receptors in a preparation, as well as their affinity. However, it is not always possible to 
do this, due to affinity limitations of the ligand leading to the requirement for impractically high 
concentrations (see below). If a satisfactory asymptote cannot be measured, it will be impossible to 
measure the Kd with any confidence as this is the concentration needed to half saturate the 
receptor. In this case, self-displacement of the ligand is used. The concentration of radioligand is 
kept constant but increasing concentrations of unlabelled ligand are added. Effectively, the specific 
activity of the radioligand is systematically reduced by dilution with non-labelled ligand. This is a 
special case of the displacement method, used for characterising the affinity of unlabelled ligands by 
determining the concentration  needed to displace half the labelled ligand (the IC50). The IC50 is not 
the same as the affinity (Ki) for the displacer ligand, as it will be influenced by both the 
  
concentration of the radioligand (L*) and its Kd (Kd*). The Ki can be found by means of the Cheong 
Prusoff equation 
Ki = IC50/(1 + L*/Kd*) (4). 
If the displacer is really identical to the labelled ligand, then equation 4 reduces to Ki =IC50/2. 
However, for iodinated ligands, the main situation where the technique is used, this is not 
necessarily the case. Peptides modified with non-radioactive iodine have been used as displacers to 
overcome this; more usually, the problem is simply acknowledged in the paper (or ignored!). It is 
also very difficult to estimate a Bmax with this technique; it relies not only on measuring the Kd 
(with its associated error) but also measuring very low amounts of ligand bound as the receptor 
approaches saturation [6, 7]. 
The Logistic-Hill equation is the basis for all fitting of binding curves. This equation is modified to 
take account of non-specific binding and can be extended to include more than one specific binding 
site. It can also be adapted to estimate an IC50 or pIC50 (ie –logIC50) for displacement experiments. 
The experimental data is fitted using a suitable non-linear regression method. A variety of software 
packages are available; perhaps the most widely used are the PRISM family from GraphPad. Typically 
the data would first be fitted to a four parameter equation that gives estimates of minimum binding, 
Bmax, Kd/pKd and n. On the basis of n and the overall goodness of fit, it might then be deemed 
more appropriate to fit the data to a two site model; the fits can be compared by means of an F-test. 
The binding curves from each experiment should be individually fitted and the means and standard 
errors calculated from these values. It should be noted the pKd is to be preferred over the Kd for 
statistical analysis, as only estimates of the former are normally distributed and so can be used with 
parametric statistics [6, 7].  
 
2.2 Radioligand binding assays  
Radioligand binding assays were largely developed in the 1970s, but remain an important tool for 
receptor characterisation. They can be equally applied to purified receptors and receptors in 
membranes. In this section, the binding of [
125
I]-CGRP to its receptors expressed in L6 myocytes is 
given as an example [8], but the technique can be readily applied to many other GPCRs. 
 
2.2.1 Ligand selection and design 
The ligand needs to have adequate specificity for the receptor under consideration. For a purified 
receptor this is much less of an issue than for one in a native cell membrane, where other receptors 
may be present. However, even here, non-specific binding to detergent micelles remains an issue. 
Hydrophobic ligands can partition into micelles; charged ligands will form coulombic interactions 
with polar or ionic groups on the solubilising agent. It may be possible to mitigate this by increasing 
the ionic strength of the buffer used for the binding assay; these frequently contain 100 mM NaCl or 
a similar salt and it is possible to use higher concentrations, although eventually this may impair 
binding to the receptor itself. It should also be noted that Na+ is an allosteric regulator at GPCRs. To 
reduce non-specific binding of a ligand to surface, it can be coated with silane or between 0.1 and 
1% bovine serum albumin can be included in the binding buffer [8]. 
The ligand must be intrinsically of high affinity, with a Kd typically of around 1nM. Much below this 
and excessive amounts of ligand need to be used. This becomes impractical both in terms of cost 
  
and safety. Furthermore, the greater the concentration of ligand, the larger will be the associated 
non-specific binding. There are also issues relating to ligand kinetics [6]. A low affinity will invariably 
mean that the ligand has a rapid dissociation rate. Most methods for separating bound from free 
ligand result in period when the receptor-ligand complex is isolated from free ligand but not yet 
captured for assay (for example, during the wash phases on a filter). A rapidly dissociating ligand 
may be almost entirely lost during this time. Ultra-high affinity ligands bring their own problems. 
They may be associated with slow and complex kinetics of association. They are particularly difficult 
to use during in competition assays, where the radioligand is present as a tracer to monitor the 
binding of a non-labelled compound. The danger is that if the radioligand binds is a pseudo-
irreversible manner, a true equilibrium with the displacer is never set up. If the ligand is simply 
needed as a marker of active receptor during solubilisation and purification, then pre-labelling with a 
high-affinity, slowly dissociating compound is often advantageous. It may also be possible to 
modulate ligand affinity, either by the ionic strength, pH and composition of the binding buffer, or 
by use of a positive or negative allosteric modulator of the binding, assuming such agents exist [7].  
Modification of the ligand should not significantly impair its properties. The most common 
modifications are substitution of 
3
H or introduction of 
125
I. The production of a 
3
H labelled 
compound, where there has been simple substitution of a 1H atom, will not change the chemical 
properties of the ligand but production of such compounds usually requires access to specialised 
chemical facilities.  
125
I is usually introduced as a substitution onto the aromatic ring of tyrosine in 
peptides. The iodine atom introduces considerable extra bulk, which may result in steric hindrance 
or the formation of new van der Waal contacts with the receptor [9]. Histidine can also be iodinated 
but the same caveats apply. If no suitable endogenous amino acid is present, then an N-terminal 
tyrosine can be introduced or the peptide modified by derivatisation with the Bolton-Hunter reagent 
[10]. In these cases, new peptides are produced and clearly they may show different properties from 
the starting compounds. Iodination can readily be performed in-house by the use of iodogen or 
other reagents but hplc purification is usually essential to purify mono-iodinated ligands. It should be 
noted that many commercially available iodinated peptides are principally used in radio-
immunoassays, where structural requirements may be less stringent than in receptor binding. The 
experimenter would do well not to assume a commercially available radioligand will be suitable for 
receptor binding, unless a stringent analysis has been reported in the literature, including a 
satisfactory measurement of Kd [7]. Thus, for the peptide adrenomedullin, the C-terminal tyrosine 
can be iodinated [9], but this residue is now known to be crucial for binding to its receptor [50]. 
2.2.2 Experimental strategy 
The design of a ligand binding assay is usually straightforward. The preparation containing the 
receptor is first mixed with any unlabelled drug, either to define non-specific binding or for use in a 
displacement assay and the incubation started by adding the labelled ligand. After sufficient time 
has elapsed to allow equilibrium to be reached, the bound and free ligands are separated and the 
fraction containing the bound ligand is analysed by scintillation counting, or whatever technique is 
appropriate to allow its quantification [6]. There are a number of important practical points that 
need to be considered. 
An appropriate buffer must be used [11]. The effects of the buffer composition on non-specific 
binding have already been noted. For GPCRs, it may be advantageous to include Mg
2+
 at low 
millimolar concentration, to promote G protein coupling to the receptor. Particularly if a peptide 
ligand is used, appropriate peptidase inhibitors may be included. Temperature will of course 
influence the kinetics of binding; the higher the temperature the faster equilibrium will be achieved 
but the binding may be less stable due to unfolding or degradation of either the receptor or ligand. 
  
The experience of the authors is that a buffer of 20mM Hepes, 1mM MgCl2, ph7.4, supplemented 
with 0.1% bovine serum albumin if a hydrophobic ligand is being used, is a good place to start, if no 
clues are available in the literature [8]. The authors normally conduct binding experiments at rom 
temperature (25C). Prior to solubilisation, a decision needs to be taken if binding will be measured in 
intact cells or a membrane preparation. For biochemical studies, membranes are usually to be 
preferred as they allow greater control of the experimental conditions; particularly useful if the G 
protein coupled state of the receptor needs to be studied (see section 3.1 for how G-protein 
association can be manipulated and also reference 11 for an application of this to the study of 
muscarinic receptors). An important practical point is that the membranes must be well dispersed, 
to give a homogeneous suspension; this can be achieved by use three, 15 second bursts of a 
polytron (e.g. Ultra Turrax T25). 
It is essential that enough time is allowed for the ligand to reach equilibrium. In competition assays, 
the time needed for equilibrium to be reached between the labelled ligand and the displacer needs 
to be considered. It may be possible to establish the time needed for an assay by reference to the 
literature, otherwise some preliminary experiments will be needed to discover this [5]. 
A further important issue is that of depletion of labelled ligand. It is normally assumed that the 
concentration of this does not change during the experiment. However, if the receptor is present in 
high amounts (as can happen with concentrated, purified receptor), then it will act as sink for the 
ligand, reducing its concentration throughout the course of the incubation. Depletion should be kept 
to less than 20%, by reducing the amount of receptor [6, 7].  
A variety of methods are available to separate bound from free ligand. For membranes, the two 
most widely used are centrifugation or filtration. In the former, tubes containing the membrane 
preparation are spun in a micro-centrifuge (preferentially one that can be cooled) to pellet the 
membranes. The supernatant is discarded and the tubes washed twice with water (taking care not to 
dislodge the pellets) before being allowed to dry. If a 3H-labelled radioligand has been used, the 
pellet needs to be dissolved in a tissue solubiliser prior to scintillation counting. The membrane 
protein concentration should be around 0.1-0.5 mg/ml. For filtration, the membranes are retained 
on filters held on vacuum manifolds (cell harvesters); they are rapidly washed two or three times 
with ice-cold buffer. Lower membrane protein concentrations can be used than with centrifugation 
assays, but the filters may need to be pre-coated with polyethyleneimine  to prevent non-specific 
binding of the ligand [6, 7].  
For soluble receptors, the main assays are either membrane filtration or gel filtration. In the former 
case, the filters are pre-treated with an agent such as polyethyleneimine, so that the receptor but 
not the ligand will stick. Gel filtration is of more general applicability; small 1ml columns containing a 
G10 or G25 resin can either be prepared in the laboratory or purchased. They are spun at low speed 
in a refrigerated microcentrifuge to ensure that the receptor with bound ligand passes rapidly 
through, to prevent dissociation [12].  For the solubilised adenosine 2a receptor, BioRad P30 mini-
spin gel filtration columns spun at 1000 g, for 4 minutes are a very effective way of measuring the 
binding of [
3
H] ZM241385 to the receptor [12]. 
In principle a scintillation proximity assay can be used, where the scintillant is coupled to the 
receptor. With this method, there is no need to separate bound from free ligand, as only the bound 
ligand will cause scintillation (ie it is a homogeneous assay). In practice this assay design is rarely 
used due to the difficulty of attaching the scintillant to the receptor [13]. 
2.3 Fluorescence-based assays. 
  
There is increasing use of fluorescent rather than radiolabelled ligands [14]. This is on grounds of 
safety and convenience, a particular issue where relatively short-lived isotopes are used such as 
125
I, 
with a half-life of 60 days. The introduction of a fluorophore into a molecule will inevitable change 
its chemical structure. For a peptide, it may be possible to conjugate a probe to an existing lysine or 
cysteine; alternatively a suitable unnatural amino acid can be introduced during synthesis. For non-
peptides, more extensive chemical modification is likely to be needed, with the introduction of both 
fluorophore and a linker. Careful characterisation will be needed to ensure the new molecule still 
has appropriate pharmacology properties (affinity, specificity, efficacy). The fluorophore itself needs 
a high quantum yield to allow detection when attached to a ligand at nM concentrations; Alexa 
Fluor-488, BODIPY and TAMRA are commonly used [15]. Fluorescent ligands can be used just as 
radioligands in heterogeneous assays where the bound and free ligands are separated. However, 
there is now much interest in homogeneous assays, where there is no need for this step. 
2.3.1 Fluorescent polarisation (FP) 
The principle behind this assay is that a ligand in solution will tumble freely and rapidly in all 
directions. By contrast, when it is bound to large receptor, its movements will be much more 
restricted. The polarisation of a fluorophore is inversely proportional to its rotation; if this is 
impeded, then polarisation of fluorescence is increased. The degree of polarisation is independent of 
the concentration of the fluorophore although the technique assumes that the intrinsic fluorescence 
of the ligand is not altered by binding to the receptor (if this is the case, then this may itself be the 
basis of the assay) [16]. There are some limitations of FP. Receptor expression must normally exceed 
1pmol/mg and if the receptor is still in membranes or cells, these may settle and disrupt the 
readings. It requires a high affinity interaction between receptor and ligand, similar to that of 
radioligand binding. The need for high amounts of receptor relative to ligand means that ligand 
depletion is often an issue. None-the-less, given an appropriate ligand, the technique can work on 
membranes as well as for solubilised receptors [16-18]. For the adenosine 2a receptor, Alexa-488, 
conjugated to the antagonist SCH442416 matched conventional radioligands in membrane binding 
assays [51]. However, development of the ligand required the use of synthetic organic chemistry, a 
technique that may not be readily available in many laboratories. 
2.3.2 NanoBRET 
Bioluminescence resonance energy transfer (BRET) relies on resonance energy transfer between a 
bioluminescent energy donor (generated by a luciferase) and a fluorescent acceptor which are in 
close proximity. As the excitation signal is generated by the luciferase, there is no need for an 
incoming light signal (with attendant problems such as photobleaching) which can limit fluorescence 
resonance energy transfer (FRET).  In Nanobret, a small luciferase, NanoLuc, is fused to the N-
terminus of the receptor. This gives a very bright light signal, which is used to excite a bound 
fluorescent ligand. This is a homogeneous assay with very little non-specific binding, so can be used 
to measure both high and low affinity interactions in membrane bound and soluble receptors [19]. 
However, it needs an engineered receptor and a suitable fluorescent ligand. The method has been 
successfully applied to both the β1 and β2 adrenoreceptors and the A3 adenosine receptor [19]. The 
limitations are the need to synthesise a suitable fluorescent ligand and also the requirement to 
engineer the receptor with the N-terminal fusion of the Nanoluc. Thus the technique cannot be used 
on native receptors and the construct may show different binding properties to the unmodified 
receptor.  
2.4 Label free techniques 
  
There are a number of techniques which do not need the ligand to be modified to allow 
measurement of its binding. They do however usually require the protein to have been purified and 
so cannot be used to characterise it in its original state in membranes. Two of the commonest 
techniques will be considered in this section. They work best when the ligand and receptor are of 
similar size; thus they are most frequently used to examine the binding of a peptide to the 
extracellular domain of a receptor (see below). It may be difficult to use this for a comparison with 
the intact receptor; more usually, relative potencies are be compared rather than absolute affinities. 
They can be used to measure low-affinity interactions that cannot be investigated by radioligand 
binding. 
2.4.1 Isothermal titration calorimetry (ITC)  
ITC measures the heat released or taken up when two molecules associate [20] and is often used to 
characterise purified proteins. An IT calorimeter has a reaction cell, containing the receptor in 
solution and a reference cell containing just buffer. Increasing volumes of ligand are titrated into the 
experimental cell and the energy needed to keep this at the same temperature as the reference cell 
is measured. From this, for each addition of ligand (a known number of moles), the total energy 
supplied (the enthalpy, ∆H) can be calculated. A plot of ∆H against the molar ratio of ligand to 
receptor gives a sigmoidal curve. The amplitude is the enthalpy of the reaction, the molar ratio at 
the mid-point of the curve gives the stoichiometry and the corresponding slope is 1/Kd [20, 21]. The 
technique is not particularly sensitive and so may require a substantial quantity of purified and 
solubilised receptor. On the other hand, the receptor does not need to be modified or attached to a 
surface. ITC has only rarely been applied to intact GPCRs [22], but it has been used successfully to 
characterise the binding of ligands to GPCR extracellular domains such as the peptides 
adrenomedullin and calcitonin to their receptors [23, 24]. For more detailed pharmacological 
analysis, the authors have synthesised fluorescent derivatives to allow fluorescent polarisation 
assays. 
2.4.2 Surface plasmon resonance (SPR) 
SPR measures the change in molecular weight in a target molecule immobilised to an electrically-
conducting surface on ligand binding. Polarised light is shone at the surface and this creates 
plasmons; waves of electron charge density. The polarised light is reflected back from the surface. 
The plasmons change the refractive index of the surface in proportion to the mass and concentration 
of the complex. Thus it is possible to monitor the extent and time course of the binding in real time. 
It is possible to use very small volumes in the flow cells [25]. The receptor does have to be 
immobilised to a surface (the chip, in SPR terminology) and this involves the engineering of a tag, 
such as multiple histidine residues or a short peptide sequence which can be recognised by an 
appropriate antibody which has been coated onto a chip [26]. The purified adenosine 2a receptor 
has been studied by SPR in detergent, in nanodiscs, in reconstituted lipid membranes or in high-
density lipoprotein particles [26, 27]. SPR is an increasingly used technique to examine directly the 
binding affinity of low-affinity ligands in drug discovery [28] as well as to probe fundamental aspects 
of GPCR activation [29].  
3. Assays of receptor activation 
A receptor, as understood pharmacologically, not only binds a ligand; if this is an agonist, it responds 
to influence the activity of the cell. Thus it is necessary not just to look at the initial binding event but 
subsequent downstream changes. If the receptor is studied in an intact cell or even in membranes, 
then a whole range of signalling events can be monitored. For GPCRs, these will be measurements of 
  
second messenger activation, reflecting G-protein coupling, or arrestin coupling, either measured 
directly or, less certainly, by a downstream signalling pathway. For a solubilised receptor, options are 
much more restricted. The most common assay is of G protein activation, but other methods are 
available to investigate changes in receptor state and agonist binding may itself be a measure of 
receptor function. When a receptor is bound to G protein, an agonist typically shows a higher affinity 
at than when the receptor is uncoupled [8] (see 3.1. below). 
Any assay of receptor activation gives two basic measurements; the potency of the agonist (EC50 or 
pEC50) and the maximum response (Emax). Underlying these is the ability of the agonist to bind to 
the receptor (affinity) and its ability to activate the receptor (efficacy). A full agonist is one which 
fully activates the receptor to which it binds; a partial agonist causes incomplete activation. It is now 
recognised that receptors may have more than one active state and these can differentiate between 
different signalling pathways. Furthermore, agonists may be able to preferentially activate one 
pathway over another. In such cases the agonist is described as showing bias; thus one agent may 
preferentially promote G protein coupling rather than recruitment of arrestin. A number of reviews 
are available that consider how to quantify efficacy and bias, but the most basic step is to fit the data 
(in the form of a concentration-response curve) to a logistic-Hill equation of a similar form to that 
used for ligand binding, to obtain the basal and Emax values, the pEC50 and the Hill coefficient. Any 
software that will analyse a binding curve will also fit a concentration-response curve [7]. It should 
be noted that the Emax is not the same as the Bmax obtained in binding assays; the number cannot 
be simply interpreted in terms of the number of receptors present. For the latter, a binding assay is 
needed. 
3.1 G protein association 
The simplest conceptional model of agonist action is that it first binds to the receptor and there is 
then a conformational change, leading to activation; this corresponds to conformational induction. 
The alternative is conformational selection, where the receptor spontaneously exists in active and 
inactive forms and the agonist preferentially binds to the active form and so, by mass action, moves 
the bulk of the population to this state. In either model, the observed Kd for the agonist reflects the 
affinity for the active form of the receptor. Similar considerations apply to the binding of an inverse 
agonist, except in this case the ligand preferentially binds to the inactive form of the receptor [7]. 
For GPCRs, agonists promote a number of conformational changes within the receptor which create 
a binding pocket for the G protein (or arrestin) and give a receptor with a high affinity for the 
agonist. G protein association can be disrupted either by GTP or a stable analogue such as GppNHp 
[7, 8, 34]. Thus in simple terms, if agonist affinity is reduced by addition of 10-100µM GppNHp, then 
this is good evidence that the receptor can couple to a G protein. This can be applied to receptors in 
membranes or solubilised receptor G-protein complexes. Evidence for G protein coupling be found 
from either the direct binding of the agonist if it is labelled, or from the ability of the agonist to 
displace a labelled antagonist. In the latter case, agonist displacement curves typically show two 
components (reflected in the first instance by the curve having a low Hill coefficient) reflecting G 
protein coupled and uncoupled populations of the receptor. Addition of GTP or an analogue should 
reduce the amount of the high affinity component. The addition of GTP is important to demonstrate 
that the multiphasic agonist displacement curve is really due to G protein coupling and not binding 
by the agonist to other receptors [31]. In more recent applications, the presence of GTP (analogue)-
shift to an agonist can be used to show the functionality of a receptor engineered for crystallisation 
[52]. 
  
For purified receptors, coupling to individual G proteins can be measured by adding each back in 
reconstitution experiments [32]. If the assay is performed on membranes made from cells, then the 
coupling cannot be controlled and will reflect the preference of the receptor in that particular 
environment. 
3.2 Other allosteric modulators 
The G-protein is a positive allosteric modulator (PAM) of agonist binding. Measuring this is of 
especial value as it is part of one of the main physiological pathways that results from agonist 
binding. However, there are numerous sites at which both positive and negative exogenous 
allosteric modulators of ligand binding can bind, ranging from the ligand entry site on the 
extracellular surface of the receptor to its cytoplasmic face. Their effects can most sensitively be 
detected by effects on receptor kinetics; thus a PAM will slow off rates and a negative modulator will 
speed this up. If a purified or engineered receptor responds to allosteric modulators in the same way 
as when in its native membrane in the wild-type state, then this is good evidence that its functional 
properties are not impaired [33]. As detection of allosteric modulators involves binding assays, they 
can be used both on membrane-bound and purified receptors; the limiting factor is the availability of 
an allosteric ligand. 
3.3 G protein activation 
3.3.1 GTPγS binding 
G protein activation may be simply assayed be measuring the association of GTPγS to the receptor- 
G protein complex. This reflects the physiological process of GDP/GTP exchange that is promoted by 
an activated receptor [34]. The assay actually reflects the rate of exchange; the active receptor acts 
catalytically to increase turnover at the guanine nucleotide binding site and so it is important an 
appropriate time is selected and that all assays use this as near exactly as possible [32]. The time 
chosen, typically between 5 and 60 minutes, will depend on the G protein (exchange at Gs is slow) as 
well as the receptor. The assay itself is a simple binding assay (thus applicable to membrane bound 
and purified receptors), normally with 35S-GTPγS as the ligand, although fluorescent versions have 
also been used; the fluorescence of BODIPY-FL-GTPγS increases on binding to G proteins and so this 
has been used in homogeneous assays for the reconstituted parathyroid receptor without the need 
to separate bound from free ligand [35]. The assay buffer needs to contain around 100nM GDP to 
suppress non-specific binding. The optimum conditions for the assay may either be established from 
the literature or by pilot experiments. If the assay is carried out in membranes, then it will reflect the 
activity of all G proteins that are present and to which the receptor can couple. Coupling to 
individual G proteins can be established if the membranes are first solubilised and individual G 
proteins are then immunoprecipated using Protein-A sepharose beads and G protein antibodies with 
appropriate specificity; critical reading of the literature may be needed to select appropriate 
reagents [36]. 
It is possible to directly measure the binding of a purified G protein to a receptor by techniques such 
as SPR or microscale thermophoresis [37-39]. 
3.4 FRET and other spectroscopic assays of receptor conformation 
It may be possible to directly measure changes in receptor conformation. One approach is to 
engineer the receptor so that it has an appropriate reporter for spectroscopic detection, using for 
example fluorescence or electron spin resonance [40, 41]. The engineering can be done in various 
ways. Many approaches are based on fluorescent reporters. Either changes in properties of the 
  
fluorophore itself may be measured as the receptor changes conformation, or a FRET signal is 
detected from a second fluorophore that is in close proximity to the first one [40, 42]. Bimolecular 
FRET is where the donor is attached to one molecule with the acceptor on a second. This method 
has been applied to GPCRs and arrestins to allow measurement of their association [43].  In 
unimolecular FRET they are both on the same protein, to allow measurement of intramolecular 
conformational changes. If luciferase rather than a fluorescent donor is introduced, then a BRET 
signal can be measured.  For GPCRs, a suitably engineered member of the Green Fluorescence 
Protein (GFP) family is usually attached to the C-terminus. For unimolecular FRET, a second 
fluorophore needs to be introduced within the sequence in such a way that it does not compromise 
receptor function. One approach is the introduction of a tetra-cys motif (CCPGCC) which reacts with 
arsenic-containing fluorophores [44]. This was pioneered with the adenosine 2a receptor. However, 
it is clear that considerable development work needs to be done to ensure that the tag is introduced 
at a location that does not impair the function of the receptor. Rather than introduce a tag, it may 
be possible to introduce a single reactive residue such as a cysteine which can react with a probe to 
label the receptor. In this case, careful consideration needs to be given to ensuring that only the 
introduced cysteine reacts with the reporter; most receptors will contain a number of free cysteines 
[40]. Some of these may be inaccessible to the label, particularly if they are in the transmembrane 
region; it may be necessary to substitute others with alanine or serine. To avoid these problems, 
some workers have used unnatural amino acid mutagenesis to directly introduce novel fluorescent 
amino acids or amino acids that can be derivatised under conditions where no other residue is 
modified [45]. In all cases, considerable work is needed to engineer a receptor that retains an 
acceptable wild-type-like phenotype but which can also be used to monitor activity. All FRET-based 
approaches require engineered receptors. 
3.5 Other methods to study receptor conformation. 
Apart from spectroscopic labels, receptors can also be engineered with cysteines for use with 
saturation cysteine scanning mutagenesis (SCAM), where cysteines are systematically introduced 
and their reactivity to a derivatising agent is monitored [46], or for their ability to form disulphide 
bonds which only occur after receptor activation (revealed by peptide mapping after protease 
digestion) [47]. Again, the production and evaluation of these constructs is not a trivial undertaking. 
If the protein has been purified, then monitoring changes in overall properties such as endogenous 
fluorescence may give a measure of receptor activation [48]. However, it is often hard to interpret 
these signals mechanistically as they reflect contributions from a number of different residues or 
regions within the protein. Sensitivity to SDS and proteases have also been used as ways of 
monitoring changes in conformation accompanying receptor activation [49].  
4 Conclusions 
There are a wide variety of techniques that can be used to study the function of purified GPCRs. 
Ligand binding lies at the heart of most assays and it is advantageous if the experimenter has a good 
theoretical grasp of how to analyse ligand-binding curves. Traditionally radioligands were used, but 
many have been replaced by fluorescent ligands, but the principles behind the assays remain 
unchanged. Ligand binding can be carried out on unmodified receptors. FRET and BRET-based 
techniques allow measurement of molecule association and intramolecular distances and these are 
increasingly applied to study receptor function. They can allow a very sophisticated analysis of 
receptor function but they need the availability of engineered receptors. 
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Appendix; equipment and suppliers 
For most of the assays described in this chapter, no specialised equipment is needed beyond that 
which would be regarded as standard; microfuges, water baths, etc. Likewise, most reagents are 
available from a range of suppliers. In this appendix some suggestions are provided for more 
specialised equipment and chemicals; this is not intended to be exhaustive. 
 
Radioligand suppliers 
Perkin Elmer (www.perkinelmer.co.uk/category/radiochemicals) 
American Radiochemicals (https://arclive.chennova.co.in) 
 
Fluorescent ligand and probe suppliers 
Abcam (www.abcam.com/index.html?pageconfig=resource&rid=14885) 
Hellobio (https://www.hellobio.com/products/type.html?picat=157) 
Thermofisher Scientific (https://www.thermofisher.com/us/en/home/references/molecular-probes-
the-handbook/probes-for-endocytosis-receptors-and-ion-channels/probes-for-neurotransmitter-
receptors.html)  
Tocris (https://www.tocris.com/product-type/fluorescent-probes) 
 
Cell harvesters 
These are used for filtration binding assays and are made by numerous suppliers; two examples are 
given below 
Perkin Elmer (http://www.perkinelmer.co.uk/category/cell-harvesters) 
Tomtec (www.tomtec.com/cell-harvester.html) 
 
Spin columns 
Bio-Rad Microspin columns (http://www.bio-rad.com/en-uk/category/bio-spin-micro-bio-spin-size-
exclusion-spin-columns) 
 
FRET and BRET-based assays 
Promega supplies suitable constructs for nanoBRET; (https://www.promega.co.uk/products/protein-
interactions/live-cell-protein-interactions/nanobret-ppi-starter-systems/?catNum=N1821)  
  
Perkin Elmer supply a variety of kits for detection of second messengers via time-resolved 
fluorescence, using their LANCE range (www.perkinelmer.co.uk/category/lance-tr-fret) 
Thermofisher Scientific supply reagents for FlAsH (https://www.thermofisher.com/uk/en/home/life-
science/cell-analysis/cellular-imaging/high-content-screening/flash-and-reash.html) 
 
Isothermal calorimeters 
Malvern (https://www.malvern.com/en/products/technology/isothermal-titration-calorimetry) 
 
Surface Plasmon Resonance (SPR) 
GE Healthcare supply Biacore instruments and reagents for SPR 
(http://www.gelifesciences.com/webapp/wcs/stores/servlet/catalog/en/GELifeSciences-
uk/products/AlternativeProductStructure_11926/) 
 
Data analysis 
Graphpad supply the PRISM software (https://www.graphpad.com/scientific-software/prism) 
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